Schizophrenia News and Research

Latest Schizophrenia News and Research

New technique may find 'hidden' receptors in nerve cells

Scientists at The Scripps Research Institute and University of Pennsylvania have found a way to uncover potential drug targets that have so far remained hidden from researchers' view.

11 Mar 2011

Future Medicine launches Neuropsychiatry

Future Medicine Ltd has today announced the launch of Neuropsychiatry – a new bimonthly title addressing all the latest trends in the field, from R&D through to clinical application and management, presenting research, findings, analysis and commentaries from experts around the world. Neuropsychiatry is published by Future Medicine Ltd (UK, London) renowned for its collection of journals providing healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in light of advances in medicine, healthcare and clinical practice.

10 Mar 2011

New study sheds 'light' on intricate brain cell connections responsible for anxiety

A new study sheds light--both literally and figuratively--on the intricate brain cell connections responsible for anxiety.

10 Mar 2011

EDT receives European approval for XEPLION injection to treat schizophrenia

Elan Drug Technologies, the drug delivery unit of Elan Corporation, plc, today announced that the first injectable product using EDT's NanoCrystal technology has been approved by the European Commission.

9 Mar 2011

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

NeuroDerm, Ltd. announced today the enrollment of the first group of patients in its Phase I/II clinical trial of ND0611, a new patch for the treatment of Parkinson's disease.

9 Mar 2011

New Australian drug approvals subject to budget cuts

According to Health Minister Nicola Roxon’s statement to pharmaceutical company bosses, new medicines will no longer be subsidised unless budget savings can be found.

9 Mar 2011

FDA accepts Lundbeck's clobazam NDA for review

Lundbeck Inc. today announced the U.S. Food and Drug Administration has accepted for review a New Drug Application for the investigational compound clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome in patients two years and older.

5 Mar 2011

Scientific symposium to examine new approaches to schizophrenia drug development

Despite significant investment in research and development by pharmaceutical companies, the last decade has seen a marked decline in the number of drugs developed and approved for schizophrenia. A multi-day symposium at the New York Academy of Sciences on Wednesday, March 9 - Friday, March 11 will convene world-leading experts in clinical, translational, and basic neuroscience to address this problem by examining novel, state-of-the-art approaches to schizophrenia drug development.

5 Mar 2011

Efficiency of brain function depends on family's genetic makeup

How well our brain functions is largely based on our family's genetic makeup, according to a University of Melbourne led study.

4 Mar 2011

Marijuana and psychosis linked in a study

...

3 Mar 2011

New study provides fascinating insight into genetic basis of bipolar disorder

A new study provides fascinating insight into the genetic basis of bipolar disorder, a highly heritable mood disorder characterized by recurrent episodes of mania and depression.

3 Mar 2011

Omeros identifies orphan GPCR compounds associated to pancreatic cancer, cognitive disorders

Omeros Corporation today announced that it has identified compounds that interact selectively with two orphan G protein-coupled receptors linked to pancreatic cancer and cognitive disorders.

3 Mar 2011

ITI, Takeda collaborate to develop and commercialize PDE1 inhibitors for schizophrenia

Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States.

3 Mar 2011

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.

2 Mar 2011

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

An experimental drug that targets a brain system that controls inflammation might help preserve neurological function in people who survive sudden cardiac arrest, new research suggests.

2 Mar 2011

New research finds link between genomic variants in neurological processes and autism

New research on the genomics of autism confirms that the genetic roots of the disorder are highly complicated, but that common biological themes underlie this complexity. In the current study, researchers have implicated several new candidate genes and genomic variants as contributors to autism, and conclude that many more remain to be discovered.

2 Mar 2011

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine as adjunctive therapy in major depressive disorder.

28 Feb 2011

New study: Immune molecules can regulate synaptic connections in brain

The number of connections between nerve cells in the brain can be regulated by an immune system molecule, according to a new study from UC Davis. The research, published Feb. 27 in the journal Nature Neuroscience, reveals a potential link between immunity, infectious disease and conditions such as schizophrenia or autism.

27 Feb 2011

Study: Rare genetic mutations may provide clues to improve treatment for schizophrenia

Scientists are eyeing a rare genetic glitch for clues to improved treatments for some people with schizophrenia - even though they found the mutation in only one third of 1 percent of patients.

25 Feb 2011

Research: Gene mutation linked to schizophrenia may aid in new drug development

In a major advance for schizophrenia research, an international team of scientists led by the University of California, San Diego School of Medicine and involving Trinity College Dublin researchers has identified a gene mutation strongly linked to schizophrenia that may be an important new target for the development of drug therapies.

24 Feb 2011

Schizophrenia News and Research

Latest Schizophrenia News and Research

New technique may find 'hidden' receptors in nerve cells

Future Medicine launches Neuropsychiatry

New study sheds 'light' on intricate brain cell connections responsible for anxiety

EDT receives European approval for XEPLION injection to treat schizophrenia

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

New Australian drug approvals subject to budget cuts

FDA accepts Lundbeck's clobazam NDA for review

Scientific symposium to examine new approaches to schizophrenia drug development

Efficiency of brain function depends on family's genetic makeup

Marijuana and psychosis linked in a study

New study provides fascinating insight into genetic basis of bipolar disorder

Omeros identifies orphan GPCR compounds associated to pancreatic cancer, cognitive disorders

ITI, Takeda collaborate to develop and commercialize PDE1 inhibitors for schizophrenia

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

New research finds link between genomic variants in neurological processes and autism

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

New study: Immune molecules can regulate synaptic connections in brain

Study: Rare genetic mutations may provide clues to improve treatment for schizophrenia

Research: Gene mutation linked to schizophrenia may aid in new drug development

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Schizophrenia News and Research

Latest Schizophrenia News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in